prostate%20cancer
PROSTATE CANCER

Prostate cancer is the cancer that occurs in the male's prostate.

It is the most common cancer in men >50 years of age.

Signs and symptoms include weak urinary stream, polyuria, nocturia, hematuria, erectile dysfunction, pelvic pain, back pain, chest pain, lower extremity weakness or numbness and loss of bowel or bladder control.

Supportive Therapy

Pharmacological Therapy

  • Mitoxantrone may be used for patients with symptomatic metastatic castration-resistant prostate cancer (CRPC) who have contraindications to Cabazitaxel or Radium-223 therapy
  • Denosumab and bisphosphonates (Eg Alendronate, Pamidronate, Zoledronic acid) may be suggested in patients with metastatic CRPC with bone metastasis to help prevent bone fractures, metastases, and other skeletal complications

Radiation Therapy

  • Recommended dose:
    • Non-vertebral metastases: 800 cGy x 1 fraction
    • Widespread bone metastases: Sr-89 or Sm-153 with or without focal external beam radiation therapy (EBRT)

Referral

  • Refer patient and his family to facilities that can provide palliative care services that can assist both the patient and his family while dealing with prostate cancer
  • Referral to pain clinics or palliative care team may also help in the symptomatic management of prostate cancer patients
Editor's Recommendations
Most Read Articles
Stephen Padilla, 2 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

5 days ago
Treatment with tradipitant in patients with idiopathic or diabetic gastroparesis produces meaningful improvements in nausea and vomiting, according to the results of a phase II trial.